Developments of Phase 3 Trial: BOSTON  Bortezomib in combination with Selinexor for treating Myeloma

Developments of Phase 3 Trial: BOSTON Bortezomib in combination with Selinexor for treating Myeloma

ASHReport

2 years
162 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON - Bortezomib in combination with Selinexor for treating myeloma at the 2017 American Society of Hematology.
Up Next Autoplay